ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue3,197.81B30,151.70M
Gross Profit1,798.37B16,956.61M
Operating income447,610M4,220.44M
Income before tax366,159M3,452.46M
Net income376,005M3,545.29M
EBITDA1,007.28B9,497.50M
Diluted EPS238.952.25
Dividends Per Share1801.69
Total Assets12,912.29B116,853.33M
Total liabilities7,735.11B70,001.05M
Total equity5,168.89B46,777.35M
Operating cash flow905,073M8,533.80M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,732.05B 1,770.53B 2,097.22B 3,291.18B 3,197.81B
Gross Profit 1,017.65B 1,148.86B 1,275.55B 1,789.37B 1,798.37B
Operating income 86,972M 195,320M 218,686M 302,612M 447,610M
Income before tax 143,346M 217,205M 127,612M -60,754M 366,159M
Net income 114,940M 186,886M 135,192M 44,241M 376,005M
EBITDA 258,398M 377,447M 466,377M 886,261M 1,007.28B
Diluted EPS 146.25 237.55 139.82 28.24 238.95
Dividends Per Share 180 180 180 180 180
Total Assets 4,346.79B 4,106.46B 13,792.77B 12,821.09B 12,912.29B
Total liabilities 2,397.82B 2,089.05B 8,606.78B 8,093.60B 7,735.11B
Total equity 1,894.26B 1,997.42B 5,181.98B 4,723.48B 5,168.89B
Operating cash flow 260,067M 379,600M 302,609M 555,410M 905,073M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 15,994.93M 15,974.84M 18,911.85M 30,270.54M 30,151.70M
Gross Profit 9,397.74M 10,365.80M 11,502.42M 16,457.72M 16,956.61M
Operating income 803.15M 1,762.30M 1,972.01M 2,783.25M 4,220.44M
Income before tax 1,323.75M 1,959.76M 1,150.74M -558.78M 3,452.46M
Net income 1,061.43M 1,686.20M 1,219.10M 406.90M 3,545.29M
EBITDA 2,386.22M 3,405.56M 4,205.58M 8,151.34M 9,497.50M
Diluted EPS 1.35 2.14 1.26 0.25 2.25
Dividends Per Share 1.66 1.62 1.62 1.65 1.69
Total Assets 39,009.18M 38,612.71M 124,612.85M 118,763.31M 116,853.33M
Total liabilities 21,518.70M 19,643.19M 77,759.25M 74,972.05M 70,001.05M
Total equity 16,999.56M 18,781.60M 46,817.41M 43,754.18M 46,777.35M
Operating cash flow 2,401.63M 3,424.99M 2,728.79M 5,108.35M 8,533.80M

Valuation Measures

Mar 2021
PER16.55
ROA2.92%
ROE7.60%
Operating margin13.99%
Profit margin11.75%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer & Director: Constantine Saroukos
  • Director, Research & Development President: Andrew S. Plump
  • Chief Medical & Scientific Officer: Michael E. Mendelsohn
  • Chief Accounting Officer & Corporate Controller: Norimasa Takeda

Shareholders

  • Nomura Asset Management Co., Ltd. (4.1%)
  • BlackRock Fund Advisors (3.2%)
  • The Vanguard Group, Inc. (2.3%)
  • Nippon Life Insurance Co. (2.2%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • Nikko Asset Management Co., Ltd. (1.9%)
  • BlackRock Japan Co., Ltd. (1.4%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.9%)
  • Baillie Gifford & Co. (0.7%)
  • Takeda Pharmaceutical Employee Incentive Plan (0.7%)

Contact Details

Related Companies

  • Takeda Pharmaceutical Co. Ltd. /5 Prescription Pharma Asset/
  • Takeda Pharmaceutical Employee Long Term Incentive Plan
  • Takeda Pharmaceutical Co. Ltd. /Prescription Pharma Ass
  • Takeda Dunboyne Biologics Ltd.
  • Plasmaspendedienst GmbH
  • Gaido Health, Inc.
  • Takeda Belgium
  • Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
  • Takeda Re Insurance AG
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Pvp Biologics, Inc.
  • Maverick Therapeutics, Inc.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.
  • Takeda Development Center Asia Pte Ltd.
  • Takeda Pharma Sp zoo

Competitors

  • AstraZeneca PLC
  • Amgen Inc.
  • Green Cross Corporation
  • Grifols, S.A. Class A
  • Roche Holding Ltd
  • CSL Limited
  • Karyopharm Therapeutics, Inc.
  • Amicus Therapeutics, Inc.
  • Protalix Biotherapeutics, Inc.
  • ADMA Biologics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • Johnson & Johnson
  • AbbVie, Inc.
  • Bayer AG
  • Merck KGaA
  • UCB S.A.
  • Swedish Orphan Biovitrum AB
  • Novo Nordisk A/S Class B
  • JCR Pharmaceuticals Co., Ltd.
  • Pharming Group NV
  • Oncopeptides AB
  • ISU Abxis Co., Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Emmaus Life Sciences, Inc.
  • BeiGene, Ltd.
  • Ipsen SA
Last Updated on 26 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more